CT Financial Advisors’s Regeneron Pharmaceuticals REGN Stock Holding History

CT Financial Advisors’s Portfolio REGN Stock Details REGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q1	$2.71K	Hold	7	–	–	﹤0.01%	540
2016 Q4	$2.57K	Hold	7	–	–	﹤0.01%	549
2016 Q3	$2.81K	Hold	7	–	–	﹤0.01%	540
2016 Q2	$2.44K	Hold	7	–	–	﹤0.01%	550
2016 Q1	$2.52K	Hold	7	–	–	﹤0.01%	554
2015 Q4	$3.8K	Hold	7	–	–	﹤0.01%	533
2015 Q3	$3.26K	Hold	7	–	–	﹤0.01%	553
2015 Q2	$3.57K	Hold	7	–	–	﹤0.01%	548
2015 Q1	$3.16K	Hold	7	–	–	﹤0.01%	549
2014 Q4	$2.87K	Buy	+7	New	+$2.75K	﹤0.01%	460
2014 Q1	$3.16K	Buy	+7	New	+$2.16K	﹤0.01%	549

Other funds holding REGN

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return

Artisan Partners Milwaukee, Wisconsin $62.3B AUM 26.25% 1-Year Est. Return

Loomis, Sayles & Company Boston, Massachusetts $74.3B AUM 24.01% 1-Year Est. Return

Polen Capital Management Boca Raton, Florida $14.5B AUM 5.7% 1-Year Est. Return

CT Financial Advisors's REGN Position: Q1 2017 in Review

CT Financial Advisors held its Regeneron Pharmaceuticals (REGN) position steady in Q1 2017 at 7 shares worth $2.71K. The position accounts for ﹤0.01% of the portfolio, ranked #540.

CT Financial Advisors first reported a position in REGN in Q1 2014 and has held it in 11 quarters since. The position peaked at $3.8K in Q4 2015. 578 funds tracked by Wall St. Rank hold REGN as of Q1 2017.

CT Financial Advisors held 7 shares of Regeneron Pharmaceuticals worth $2.71K as of Q1 2017.
CT Financial Advisors left its Regeneron Pharmaceuticals share count unchanged in Q1 2017.
Regeneron Pharmaceuticals made up ﹤0.01% of CT Financial Advisors's portfolio in Q1 2017, its #540 holding.
CT Financial Advisors first reported a position in Regeneron Pharmaceuticals in Q1 2014 and has held it in 11 quarters since.
CT Financial Advisors's Regeneron Pharmaceuticals position peaked at $3.8K in Q4 2015.
578 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q1 2017.

Based on CT Financial Advisors's 13F filing for Q1 2017, filed 7 Apr 2017.